NL-OMON42303已完成不适用
Pharmacogenetics of Mitotane - Pharmacogenetics of Mitotane
Maxima Medisch Centrum0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients >=18 years.
- •Histological proven ACC.
- •The patient has been treated with mitotane > 24 weeks.
- •Preferably >= 1 or more mitotane measurements >= 14mg/L in the two months prior to inclusion.
- •Informed consent through the ENS@T database and/or
- •Informed consent if patients will be approached separately for the donation of one EDTA of blood
排除标准
- •No mitotane dose known at the time of plasma concentration measurements.
- •Simultaneous treatment with chemotherapy.
研究者
相似试验
已完成
不适用
Pharmacokinetic modeling of mitotanecancer of the adrenal cortex10001353adrenocortical carcinomaNL-OMON37374Maxima Medisch Centrum10
招募中
4 期
Mitotane Therapeutic Drug Monitoring Study: Assessing Mitotane Pharmacodynamics in Adrenocortical Cancer in Children and AdultsAdrenocortical cancerCancer - Other cancer typesACTRN12613000058774Calvary Mater Newcastle60
已完成
不适用
Evaluation the effect of adding methylprednisolone to mitoxantrone on progressive multiple sclerosis treatmentMultiple Sclerosis.Demyelinating diseases of the central nervous systemIRCT201107145943N3Yazd University of Medical Sciences70
进行中（未招募）
不适用
Aspects Pharmacogénétiques et Pharmacocinétiques de la réponse à la CHimiothérapie d’induction par Docetaxel, Cisplatine et 5-Fluorouracile (TPF), des cancers OREUCTR2008-006874-14-FRCHU de Nîmes
已完成
1 期
Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome InjectionNeoplasmsNCT02043756CSPC ZhongQi Pharmaceutical Technology Co., Ltd.20